TOLMARsync®

The most advanced Practice and Patient Management System that delivers the tools you need so your patients get the care they deserve.     TOLMARsync Delivers… Inventory optimization Early injection warning Injection scheduling optimization Comprehensive reporting Broad EHR integration functionality Integrated benefit verification portal Plus… Multi-site contract commitment tracking System customization capabilities Quick and simple scanner installation […]

Dendreon Announces Results of New PROCEED Registry Analysis Showing Overall Survival Benefit with PROVENGE®in Men with Metastatic Prostate Cancer

– Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with PROVENGE in African-American Patients – – Results Presented in Oral Session at AUA 2017 – – Prostate Cancer Disproportionately Affects African-American Men, Who Have Twice the Mortality Rate of Caucasian Men – May 13, 2017 11:20 AM Eastern Daylight Time SEAL BEACH, Calif.–(BUSINESS WIRE)–Dendreon […]

Bone metastases in prostate cancer

Can we be doing more? Multiple symptoms are associated with bone metastases, managing these symptoms can have a significant impact on patient care. Symptomatic bone disease symptoms include: Fatigue generalized weakness1 Interference with sleep2 Dyspnea1 Impaired mobility1 Mild sensory loss, numbness1 Loss of bladder and bowel function1 Neurological impairment3 Pain and discomfort1,2 Weakness in extremities1 […]

UroGPO / Astellas XTANDI In-Practice Educational Program

New trial data added to XTANDI Prescribing Information In support of our UroGPO member practices and the UroGPO / Astellas XTANDI contract, over the next few months, we are conducting XTANDI In Practice Educational Programs for dozens of member practices across the country. These programs are designed to increase the level of education on the XTANDI therapy, appropriate […]

Speak to Your Bayer Key Account Executive Today

Bayer HealthCare thanks you for being a valued customer. The fourth quarter is an ideal time to meet with your Bayer Key Account Executive to review your 2016 utilization and to discuss your 2nd half QAR or Quarterly Average Rebate (based on half year periods). Your Bayer Key Account Executive is a partner for: Sharing […]

Improve Detection & Patient Management

Blue Light Cystoscopy With Cysview® Recommended To Enhance Treatment of NMIBC Bladder tumor viewed under white-light      Bladder tumor viewed under blue-light   “In a patient with Non-Muscle Invasive Bladder Cancer, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence.” – 2016 Guidelines for […]